Related Experiment Video
Updated: Aug 5, 2026
09:41
An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells
Published on: July 15, 2015
[The prognostic relationship between CD56 expression and newly diagnosed multiple myeloma]
C Y Geng1, G Z Yang1, H J Wang1
1Department of Hematology, Beijing Chaoyang Hospital, Capital Medical University, Beijing 100020, China.
Zhonghua Nei Ke Za Zhi
|January 28, 2022
Summary
CD56 expression in newly diagnosed multiple myeloma (NDMM) patients is a favorable prognostic factor. This indicates that CD56 positivity is associated with longer progression-free survival (PFS) in NDMM.
Area of Science:
- Hematology
- Oncology
- Immunology
Background:
- Multiple Myeloma (MM) is a hematologic malignancy.
- Prognostic markers are crucial for tailoring treatment strategies in MM.
- CD56 expression on myeloma cells is a potential biomarker.
Purpose of the Study:
- To investigate the prognostic significance of CD56 expression in newly diagnosed multiple myeloma (NDMM).
- To evaluate the association between CD56 expression and patient survival outcomes.
Main Methods:
- Retrospective analysis of 332 NDMM patients.
- CD56 expression assessed by flow cytometry prior to therapy.
- Propensity score matching used to control for confounding factors.
- Overall Survival (OS) and Progression-Free Survival (PFS) were analyzed.
Main Results:
- CD56 positivity rate was 65.1% in the study cohort.
- CD56 expression was associated with significantly longer median PFS (28.7 vs. 24.1 months, P=0.013).
- Propensity score matching confirmed CD56 positivity predicted longer PFS (34.2 vs. 25.1 months, P=0.047).
Conclusions:
- CD56 expression is a favorable prognostic indicator for progression-free survival in NDMM patients.
- This finding supports the use of CD56 as a biomarker in MM management.
- Further research may explore the mechanisms underlying CD56's impact on MM progression.
